

August 17, 2024

To The Secretary, Listing Department BSE Limited(SME), Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai-400 001

Dear Sir,

Sub: Submission of Investor Presentation to be made to Analysts/Investors

Please find enclosed herewith the investor presentation to be made to Analysts/Investors on the Financial Results of Prevest Denpro Limited for the quarter ended June 30, 2024.

This presentation is being submitted in compliance with Regulation 30(6) of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, as amended.

The same is also being made available on the Company's website www.prevestdenpro.com

This is for your information and records.

Thanking You,

Yours faithfully, For Prevest Denpro Limited

AMAN Digitally signed by AMAN SADHOTRA SADHOTRA Date: 2024.08.17 12:59:37 +05'30'

Aman Sadhotra Compliance officer and Company Secretary

Prevest Denpro Limited, CIN: L85199JK1999PLC001969, Registered Office & Factory: Unit II, Export Promotion Industrial Park (EPIP), Bari Brahmana, Jammu (J&K)-181133,India. Phone: + 0191 350 6858, 8899074151, E-mail: info@prevestdenpro.com, Web: www.prevestdenpro.com







Empowering Smiles Worldwide with Innovative Dental Solutions

Q1 FY 2025











Inside the Presentation

About the Business

- Strategic Production Selection Criteria
- Our Evolving Business Model
- Top 10 Revenue-Generating Products
- Prevest Research Centre
- Accreditations that speaks to our **Comprehensive Standards**
- Strategic Technical Research & Tie-Up
- Top 5 Exporting Countries
- Revenue Breakdown

Financial Highlights

Balance Sheet Summary **Cash Flow Summary** Income Statement



Quarterly Highlights

P&L Summary Management Commentary





Market Statistics

Strategic Product Selection Criteria

At Prevest Denpro Limited, our strategic product selection is driven by the following five key criteria:

Market Demand & Growth Potential Target products with strong demand and significant growth potential in the dental industry.

Prioritize innovative products that leverage cutting-edge technology to meet emerging market needs.

Profitability & Scalability

Focus on products with high profit margins and scalability to maximize return on investment.

Prevest DenPro

Innovation & Technological Advancement

> **Regulatory Compliance** & Quality Standards Ensure all products adhere to global regulatory requirements and maintain the highest quality standards.

Competitive Advantage & Differentiation

Select products that offer unique features and align with the Prevest Denpro brand for a competitive edge

Our Evolving

Business Model

Diversification Strategy

Prevest Denpro Limited is committed to expanding its market reach and product portfolio. Our evolving business model emphasizes diversification across various dental product segments, including:

- Innovative Dental Materials
- Advanced Equipment
- Digital Solutions

Global Expansion

We are strategically broadening our presence in international markets to capitalize on growth opportunities. Our approach includes:

- Market Penetration
- Strategic Partnerships
- Localization

Innovation and R&D Focus

Innovation is at the core of our business model. We invest significantly in research and development to:

- Develop New Products
- Enhance Existing Offerings
- Collaborate with Experts

Sustainability and Efficiency

We are dedicated to integrating sustainable practices and improving operational efficiency by:

- Eco-friendly Practices
- Operational Excellence
- Quality Assurance

Customer-Centric Approach

Our evolving business model prioritizes customer satisfaction by:

- Feedback Integration
- Training and Support
- Customized Solutions

Digital Transformation

We are embracing digital technologies to modernize our operations and engage with customers more effectively, including:

- E-Commerce Platforms
- Data Analytics
- Digital Marketing

Q1 FY25

Top 10 Revenue-Generating Products



Prevest DenPro





Prevest Research Centre



UNLOCKING INNOVATION: THE IMPACT OF PREVEST DENPRO'S RESEARCH CENTRE

Innovation & Development: Creates advanced dental materials and technologies.

Quality Enhan durability.

Customization needs.

Faster Time-to launches.

Cost Efficiency manufacturing.

Intellectual Property: Strengthens proprietary technologies.

Regulatory Co certification.

Sustainability: Develops eco-friendly and sustainable products.

Collaboration: Partners with experts for cutting-edge solutions.

Brand Reputation: Reinforces commitment to quality and innovation.

Quality Enhancement: Ensures high safety, efficacy, and

Customization: Delivers tailored solutions for specific client

Faster Time-to-Market: Accelerates product development and

Cost Efficiency: Reduces R&D costs and optimizes

Regulatory Compliance: Facilitates global market entry and

Comprehensive Standards

CE 0123

Conformity with European Standards



Conformity with ISO Standard For Medical Devices



الهيئة الصامة للضخاء والحواء Saudi Food & Drug Authority

Conformity to sell our products in Saudi Market



Prevest DenPro



Conformity to sell our products in US Market



Conformity to Medical Device Single Audit Program for USA, Canada & Brazil

Strategic Technical

Research & Tie-Up

Prevest DenPro Limited has partnered with esteemed dental and technical institutions across India to advance research and innovation in dentistry and oral care. Collaborations with institutions like Terna Dental College & Hospital, Malla Reddy Dental College for Women, and Guru Nanak Institute of Dental Sciences and Research focus on clinical research and advanced dental technologies. These partnerships aim to improve patient care and health outcomes by setting higher standards in dental practice. We are grateful to our partners for their invaluable contributions and look forward to continued success in enhancing dental healthcare



Swargiya Dadasaheb Kalmegh Smruti Dental College and Hospital, Maharashtra

Prevest DenPro

Top 5 Exporting Countries

United Kingdom

Indonesia

10.13% Revenue

Saudi Arabia

9.12% Revenue

17.03% Revenue



Morocco



7.43% Revenue

3.60% Revenue

Revenue Breakdown

Domestic Sales vs. Export Sales

	2023-24	2023-24	2024-25		
Particulars	Qtr 1	Qtr 4	Qtr 1	Qtr on Qtr	Prev Qtr /Current Qtr
Domestic Sale	4.98 Cr	5.74 Cr	6.20 Cr	24.50%	8.01%
Sale Export	8.29 Cr	10.40 Cr	6.93 Cr	-16.41%	-33.37%
Revenue from Sale	13.28 Cr	16.16 Cr	13.13 Cr	-1.13%	-18.75%

Financial Highlights

Prevest DenPro



FINANCIAL HIGHLIGHTS

Balance Sheet Summary

					(INR cr)
As on 31st March	FY20	FY21	FY22	FY23	FY24
Equity share capital	0	0	12	12	12
Preference Share Capital	0	0	0	0	0
Reserves & surplus	14	22	45	61	77
Shareholders funds	15	22	57	73	89
Borrowings	1	2	1	1	0
Net Deferred tax	0	0	0	0	1
Minority interest	0	0	0	0	0
Sources of funds	16	24	59	75	75
Net block	4	5	7	7	27
Capital work in progress	0	2	5	17	0
Total fixed assets	5	7	11	24	27
Investments	0	0	1	1	2
Inventories	1	1	3	5	6
Sundry debtors	2	4	2	4	8
Cash and equivalents	10	16	42	39	48
Loans and advances	3	2	4	5	4
Other current assets	0	0	0	0	0
Total current assets	17	23	52	53	66
Sundry creditors and others	4	6	5	5	5
Provisions	1	1	0	0	1
Total CL & provisions	5	7	5	5	6
Net current assets	12	17	47	48	60

FINANCIAL HIGHLIGHTS

Cash Flow Statement

Year to March	FY20	FY21
Net profit	5	7
Add: Depreciation	1	0
Add: Misc expenses written off	0	0
Add: Deferred tax	0	0
Gross cash flow	6	8
Less: Changes in W. C.	1	-1
Operating cash flow	5	9
Less: Capex	1	2
Free cash flow	4	7

FY22	FY23	FY24
12	16	16
1	1	1
-1	-2	-2
0	0	0
11	15	15
6	4	4
5	11	11
5	14	4
0	-3	7

FINANCIAL HIGHLIGHTS

Income Statement

Year to March	FY20	FY21	FY22	FY23	FY24
Income from operations	23	28	38	50	56
Direct costs	7	8	10	13	14
Power & Fuel	0	0	0	0	0
Employee costs	5	5	7	8	9
Other expenses	6	7	7	9	13
Total operating expenses	18	20	23	30	36
EBITDA	5	9	15	20	20
Depreciation and amortisation	1	0	1	1	1
EBIT	5	8	15	19	19
Interest expenses	0	0	0	0	0
Profit before tax	6	9	16	21	21
Provision for tax	1	2	4	5	5
Extraordinary items	0	0	0	0	0
Profit after tax	5	7	12	16	16
Adjusted net profit	5	7	12	16	16
Equity shares outstanding (mn)	0.9	0.9	1.2	1.2	1.2
EPS (INR) basic	6	8	10	13	13
Diluted shares (Cr)	0.9	0.9	1.2	1.2	1.2
EPS (INR) fully diluted	6	8	10	13	13
Dividend per share	0	0	0	0	-1

(INR crs)

Quarterly Highlights

P&L Summary <u>Management Co</u>mmentary

Profit & Loss Summary

YoY Change

PARTICULARS (₹ IN CRORES)	Q1FY24	Q4FY24	Q1FY25	YoY Change	QoQ Change
Revenue from Operations	1339.40	1623.51	1335.56	-0.29	-17.74
Total Income	1399.92	1707.50	1421.99	1.58	-16.72
Operating Expenses	516.67	706.89	650.49	25.90	-7.95
EBITDA (Excluding OI & EI)	557.11	683.60	538	-3.43	-21.30
EBITDA %	39.80	40.04	37.83	-4.95	-5.52
Finance Cost	_	-	-	_	-
Depreciation & Ammortization	17.49	46.14	47.69	172.67	3.36
PBT	539.62	637.47	490.31	-9.14	-23.09
PAT	408.45	477.32	367.27	-10.08	-23.06
EPS (₹)	3.40	3.98	3.06	-10	-23.12

1.58% -3.43% EBITDA	-10.08% PAT
----------------------------	----------------

Management Commentary

Dear Investors,

As we review the results of the first quarter of FY25, I want to be upfront about our Q1FY25 performance, which did not meet our expectations. While our domestic business continues to grow strongly with 25% year-on-year growth, our export segment has faced some unexpected market challenges. The Foreign exchange crisis in many countries, the recessionary trend in Europe due to Russia – Ukraine prolonged war and the Israel – Hamas conflict have all impacted our export growth.

Additionally due to changes in European Medical Device Regulations, global dental care industry is going through significant changes and moving towards a more organized structure, Many non EU countries have also adopted EU new regulations that has impacted the growth in the international market. Our regulatory team is helping our buyers to comply with the new norms.

The strong sales in the previous quarter, where our distributors stocked up to meet their year end targets, has created a less favourable comparison for the current quarter, temporarily impacting our overall revenue growth.

However we are making efforts to increase our business in USA where our products have been approved many buyers. We are also exploring entry into new markets to drive our export growth.

Our new Oradox Advanced Oral Care product line has also received a positive response in the domestic market We remain confident that with our continued efforts for growth, we will be able to improve our export business and with greater focus on the domestic market, our overall business is expected to grow in FY25

Thank you for your continued trust and support. We're committed to driving Prevest Denpro forward, and we're confident that the best is yet to come.

Atul Modi Chairman

Management Commentary

This quarter has been challenging for us, with our numbers reflecting a less impressive performance compared to previous periods, which is mainly because of (1) higher depreciation due to commencement of new departments (R&D, Expansion), (2) Revenue expenses influencing period more than one year (Exhibitions, etc), (3) External factors like foreign markets, etc. As such, revenue though marginally increased by 1.48% year-on-year but saw a decline of 16.85% quarter-on-quarter. Similarly, our profit after tax (PAT) decreased by 10.60% year-on-year and 21.70% quarter-on-quarter. Our EBITDA also saw a decline of 3.94% year-on-year and 20.39% quarter-on-quarter.

The decrease in our margins and PAT is largely attributed to increased expenses. Depreciation expenses surged by 172% year-on-year, while exhibition and marketing expenses rose by 125%. Additionally, tour and travel expenses increased by 75% year-on-year. These cost increases have significantly impacted our bottom line, especially in a quarter where our topline growth did not meet our expectations.

However, we are not just focusing on the short-term challenges. We are actively exploring opportunities for inorganic growth, including potential acquisitions in our export business. This strategic move is aimed at positioning ourselves better for future growth and ensuring that we can tackle challenges more swiftly. Rest assured, we are committed to our long-term vision. The steps we are taking now are intended to yield sustainable growth and improved financial performance. We remain optimistic about the upcoming quarters and are confident that we will see positive developments in both our business operations and financial results.


Namrata Modi CFO

Management Commentary

In Q1 FY25, our revenue increased by a modest 1.48% year-on-year, but there was a 16.85% decline quarter- on-quarter. While this performance did not meet our expectations, I want to assure you that we are taking deliberate and strategic actions to boost our topline in the coming quarters. In the domestic market, we are focusing on expanding our presence in the East and South regions of India, which currently lag behind our performance in the North and West. To overcome this, we have established a dedicated marketing team under my leadership to penetrate these regions. We are introducing new schemes, continuing to send samples, and organizing training and awareness camps in collaboration with local institutes and distributors to increase product visibility. We are also working diligently on customer engagement by maintaining regular contact with our distributors and potential customers, providing hands-on demonstrations and live usage sessions conducted by experienced professionals. We are well aware of the areas where our performance needs improvement and have devised an execution plan to address these gaps.

The impact of these efforts will be visible in the coming quarters. Our proactive approach to increasing our marketing presence is already showing results, as evidenced by the 25% year-on-year growth in our domestic market. Although this growth may seem gradual, it is the foundation of a strong, sustainable future. The decline in overall revenue this quarter is temporary and primarily due to challenges in our export business, which were beyond our control. However, we are confident that as these obstacles are resolved, our growth trajectory will return to its previous pace, with the potential to reach or exceed 30% growth in the coming periods.

Vaibhav Munjal Chief Marketing Officer



RRENT MARKET PRICE	₹ 547
WEEK HIGH/LOW	₹ 673 / 332
RKET CAPITALIZATION	₹ 656.56 Cr
ARES OUTSTANDING	1.20 Cr
SCRIP CODE	543363
Market Price Data as on 16 th August 2024	

Thank You

www.prevestdenpro.com
www.prevestdirect.com

Prevest DenPro

